DZ Bank Reaffirms “Buy” Rating for Bayer (BAYN)

DZ Bank reaffirmed their buy rating on shares of Bayer (FRA:BAYN) in a research note released on Monday.

Other equities research analysts also recently issued reports about the company. Warburg Research set a €121.00 ($144.05) target price on Bayer and gave the stock a buy rating in a report on Wednesday, September 13th. J P Morgan Chase & Co reissued a buy rating on shares of Bayer in a research note on Friday, October 20th. UBS set a €125.00 ($148.81) price objective on Bayer and gave the company a buy rating in a research note on Tuesday, August 29th. Independent Research set a €120.00 ($142.86) price objective on Bayer and gave the company a neutral rating in a research note on Wednesday, August 23rd. Finally, equinet set a €118.00 ($140.48) price objective on Bayer and gave the company a buy rating in a research note on Friday, September 15th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of Buy and an average target price of €122.19 ($145.46).

Shares of Bayer (BAYN) opened at €106.40 ($126.67) on Monday. Bayer has a one year low of €93.07 ($110.80) and a one year high of €123.82 ($147.40).

COPYRIGHT VIOLATION WARNING: “DZ Bank Reaffirms “Buy” Rating for Bayer (BAYN)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/12/14/dz-bank-reaffirms-buy-rating-for-bayer-bayn.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply